Cover Image


Global Asthma & COPD Market Report: 2015 Edition

出版商 Koncept Analytics 商品編碼 339816
出版日期 內容資訊 英文 56 Pages
Back to Top
全球氣喘、慢性阻塞性肺病市場:2015年 Global Asthma & COPD Market Report: 2015 Edition
出版日期: 2015年09月18日 內容資訊: 英文 56 Pages



第1章 概要

  • 氣喘定義
  • 氣喘的種類
  • 氣喘的起因
  • 氣喘的治療選項
  • 慢性阻塞性肺病 (慢性阻塞性肺病)

第2章 市場分析

  • 全球呼吸系統市場
  • 全球氣喘/慢性阻塞性肺病市場
  • 全球重病氣喘市場

第3章 地區市場

  • 美國
  • EU

第4章 市場動態

  • 成長推動因素
  • 主要趨勢與發展
  • 課題

第5章 競爭情形

  • 全球呼吸系統市場
  • 全球重病氣喘市場

第6章 企業簡介

  • 產業概要、財務概要、產業策略等
    • AstraZeneca
    • Merck and Co.
    • Roche
    • Sanofi
    • Novartis



Asthma is a common chronic disease linking the airway in the lungs that affects the people of all age groups. The airways or bronchial tubes, allow air to come in and out of the lungs. The airway of asthmatic patients is generally inflamed and becomes swollen over time. This makes it difficult for air to move in and out of the lungs, causing symptoms such as coughing, wheezing, shortness of breath and/ or chest tightness.

The prevalence of asthma is expected to increase significantly in the coming years. The market for asthma drugs is driven by various factors including increasing global spending on medicines, increasing tobacco and cigarette consumption, rising prevalence of non-communicable diseases, more use of biologics, and increasing healthcare expenditure worldwide. The major upcoming trends in the asthma market include introduction of new severe asthma and Chronic Obstructive Pulmonary Disease (COPD) drugs, and introduction of new mechanisms that will help drive the market. However, there are certain challenges hindering the growth of the market. Such challenges include increased pricing pressures, patent expiries and introduction of generic drugs in the market.

The market for asthma and COPD drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancements in technology, a large number of companies are focusing to develop innovative asthma and COPD drugs and treatments. Further, the companies are combining businesses and spending comprehensively on research and development to develop effective treatment methods for asthma.

The present report provides a comprehensive analysis of the global asthma & COPD market with focus on regions like the U.S. and European Union. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules. The leading players operating in the industry include AstraZeneca, Merck and Co., Roche, Sanofi and Novartis which are also profiled in this report.


Table of Contents

1. Overview

  • 1.1. Definition of Asthma
  • 1.2. Types of Asthma
  • 1.3. Triggers of Asthma
  • 1.4. Treatment Options for Asthma
  • 1.5. Chronic Obstructive Pulmonary Disease (COPD)
    • 1.5.1. Difference between Asthma and COPD
    • 1.5.2. Treatment Options for COPD

2. Market Analysis

  • 2.1. Global Respiratory Market
    • Market Value
    • Market Segments
    • Regional Breakdown
  • 2.1.1. Global Respiratory Therapeutics Market
    • Market Value
    • Product Segmentation
  • 2.1.2. Global Inhalation Drug Delivery Technologies Market
    • Market Value
    • Product Segmentation
  • 2.2. Global Asthma/COPD Market
    • Market Value
    • Prevalence Rate
    • Regional Breakdown
  • 2.2.1. Global Asthma/COPD Therapeutics Market
  • 2.3. Global Severe Asthma Market

3. Regional Markets

  • 3.1. The U.S.
    • Market Overview
    • Diagnosed/Treated Population
  • 3.2. European Union
    • Market Overview
    • Diagnosed/Treated Population

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Growing Global Spending on Medicines
    • 4.1.2. Cigarette and Tobacco Consumption
    • 4.1.3. Rising Prevalence of Non Communicable Diseases
    • 4.1.4. Increasing Use of Biologic Drugs
    • 4.1.5. Escalating Global GDP
    • 4.1.6. Global Healthcare Expenditure
  • 4.2. Key Trends and Developments
    • 4.2.1. Launch of New Severe Asthma Drugs
    • 4.2.2. Introduction of New COPD Drugs
  • 4.3. Challenges
    • 4.3.1. Increased Pricing Pressure
    • 4.3.2. Patent Expiries and Generic Drugs

5. Competitive Landscape

  • 5.1. Global Respiratory Market
  • 5.2. Global Severe Asthma Market

6. Company Profiles

  • 6.1. AstraZeneca
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Merck and Co.
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Roche
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Sanofi
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies
  • 6.5. Novartis
    • 6.5.1. Business Overview
    • 6.5.2. Financial Overview
    • 6.5.3. Business Strategies

List of Charts

  • Treatment Guidelines for Asthma
  • Global Respiratory Market (2012-2018E)
  • Global Respiratory Market by Conditions (2014E)
  • Global Respiratory Market by Regions (2014E)
  • Global Respiratory Therapeutics Market (2010-2015E)
  • Global Respiratory Market by Drugs (2014E)
  • Global Inhaled Maintenance Respiratory Market by Value (2008-2025E)
  • Global Inhaled Maintenance Respiratory Market Volume by Prescription Equivalents (2008-2025E)
  • Global Inhalation Drugs Delivery Technologies Market (2013-2018E)
  • Global Inhalation Drug Delivery Technology by Products (2014)
  • Global Active Asthma Prevalence, Diagnosed and Treated Population (2014)
  • Global Asthma Market by Value (2012-2022E)
  • Global COPD Prevalence Rate by Countries (2014)
  • Global COPD Severity by Country (2014)
  • Global COPD Market by Value (2012-2022E)
  • Global Asthma/COPD Market by Region (2017E)
  • Global Asthma/COPD Therapeutic Market (2010-2015E)
  • Global Severe Asthma Biologics Market Forecast (2013-2022E)
  • Global Severe Asthma Biologics Market by Drugs (2022E)
  • The U.S. Asthma Diagnosed Population (2015E-2025E)
  • The U.S. Asthma Treated Population (2015E-2025E)
  • The U.S. PRS-080 Product Market and Penetration Rate (2021-2025E)
  • EU Asthma Diagnosed Population (2015E-2025E)
  • EU Asthma Treated Population (2015-2025E)
  • EU PRS-080 Product Market and Penetration Rate (2022-2025E)
  • Global Spending on Medicines (2007-2017E)
  • Global Cigarettes Consumption (1910-2014)
  • Global Deaths Occurred by NCDs by Region (2012)
  • Global Biologics Market (2008-2014E)
  • Global Gross Domestic Product Growth (2009-2014)
  • Global Healthcare Expenditure Per Capita (2009-2014E)
  • Global Respiratory Market Share by Company (2014)
  • Global Severe Asthma Market Share by Company (2022E)
  • AstraZeneca Revenue by Therapeutic Segment (2013/2014)
  • AstraZeneca Revenue by Regions (2013/2014)
  • AstraZeneca Revenue and Net profit (2010-2014)
  • AstraZeneca Pipeline Development Projects (2012-2014)
  • Merck and Co. Revenue by Segments (2013/2014)
  • Merck and Co. Revenue by Regions (2014)
  • Merck and Co. Revenue and Net Income (2010-2014)
  • Merck and Co. Research and Development Expenditure (2010-2014)
  • Roche's Revenue by Business Segments (2014)
  • Roche's Revenue and Net Income (2010-2014)
  • Sanofi Revenue by Segments (2013/2014)
  • Sanofi Revenue by Regions (2013/2014)
  • Sanofi Sales and Net Income (2010-2014)
  • Novartis Revenue by Business Segments (2014)
  • Novartis Revenues (2010-2014)

List of Tables

  • Common Asthma Triggers
  • Distinguishing Feature of Asthma and COPD
  • Treatment Guidelines for COPD
  • Investigational Treatment for Severe Asthma
  • Selective New Drugs for COPD
  • Global Respiratory Market by Company (2011-2015E)
Back to Top